Concerning the underlying mechanism for this specific AE, it has been demonstrated an increase in tumour-infiltrating lymphocytes in samples from patients after the beginning of BRAF inhibitor therapy, and the extent of infiltration correlates with tumour response. This evidence concerns the gene BRAF and neoplasm.